News

Inhibitex has posted a net loss of $4.8m for the first quarter 2010, or $ 0.08 per diluted share, compared to $4.20m, or $ 0.10 per diluted share,

As per the terms of the agreement, Pfizer will support the completion of the ongoing Phase 2 trial for Terguride and will have exclusive worldwide rights excluding Japan

Zydus Cadila has claimed that with this, it will become the first Indian pharma company to launch its vaccine which will be marketed under the brand name VaxiFlu-S.

Reportedly, preclinical studies have shown that Omeros’ proprietary, fully human, monoclonal MASP-2 antibodies shut down the lectin pathway of the complement system, which is part of the immune

Aventis Pharma said that SITE is the first cross-sectional study to assess the prevalence of diagnosed and undiagnosed cases of diabetes and hypertension amongst nearly 20,000 patients visiting

Bioject Medical has reported a first quarter 2010 net loss allocable to common shareholders of $568,000 compared to net loss allocable to common shareholders of $237,000 in the

Specifically, in a pig model, subjects with deep tissue wounds that were administered 200mcgs of Vitaros healed four times faster than those receiving placebo over a 21-day period.

Cell Therapeutics said that the proposed trial design is to test two different dosing schedules of Pixantrone. Patients on the trial are expected to be randomised to receive

Strides said that Vecuronium is a nondepolarising neuromuscular blocking agent claimed to possess all of the characteristic pharmacological actions of this class of drugs (curariform). Vecuronium is about